Risk of Venous Thromboembolism Linked with Comorbidity, Prostate Cancer
the Cancer Therapy Advisor take:
Increased venous thromboembolism (VTE) rates were clinically associated with prostate cancer (PC) and high comorbidity levels in patients, according to an article published online in the journal Cancer.
Participants in the study included 44,035 Danish patients with PC (diagnosed between 1995 and 2011) and 213,810 men from the general population. The participants were matched 5:1 on age, calendar time, and comorbidities.
Results showed 849 of the patients with PC and 2,360 of the men developed VTE within 5 years of follow-up. The patients with PC had a 2.2% risk of developing VTE, while the general population male group had a 1.3% risk.
Patients with PC and high comorbidity levels had a 1-year standardized VTE rate of 15 per 1,000 person-years (PYs) (95% CI: 6.8, 24 per 1,000 PYs)—29% of this rate was attributed to an interaction between PC and comorbidity.
Older patients, patients with metastases, those with a high Gleason score, those in the D’Amico high-risk group, and patients who had surgery were also at a greater risk for developing VTE.
The study suggests that controlling and reducing VTEs associated with comorbidities may influence the overall risk of developing VTE and potentially affect prognosis.
Editor's note: The original version of this article stated that there was a clinical association between pancreatic cancer and VTE, the article has been corrected to reflect the association between VTE and prostate cancer.
Increased venous thromboembolism rates were clinically associated with prostate cancer and high comorbidity levels.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer